Prognostic Factors in Stage IB Gastric Cancer after Surgical Resection

Yu, Byunghyuk; Park, Ji Yeon; Park, Ki Bum; Kwon, Oh Kyoung; Lee, Seung Soo; Chung, Ho Young

doi:10.5230/jgc.2020.20.e30

Cited by 9 publications

(14 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, most of the previous studies combined LI and VI together and investigated the effects of prognosis on lymphatic and vascular invasion together [ 22 – 24 ]. Individual studies of LI and VI are scattered.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The role of vascular invasion and lymphatic invasion in predicting recurrent thoracic oesophageal squamous cell carcinoma

Yao

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

Background Numerous studies have addressed lymphovascular invasion (LVI) in patients with thoracic oesophageal squamous cell carcinoma (ESCC); however, little is known about the individual roles of lymphatic invasion (LI) and vascular invasion (VI). We aimed to analyse the prognostic significance of LI and VI in patients with thoracic ESCC from a single centre. Methods This retrospective study included 396 patients with thoracic ESCC who underwent oesophagectomy and lymphadenectomy in our hospital. The relationship between LI, VI and the other clinical features was analysed, and disease-free survival (DFS) was calculated. Survival analysis was performed by univariate and multivariate statistics. Results Briefly, VI and LI were present in 25.8% (102 of 396) and 23.7% (94 of 396) of ESCC patients, respectively, with 9.15% patients presenting both LI and VI; the remaining patients did not present LI or VI. We found that LI was significantly associated with pN stage (P<0.001) and pTNM stage (P<0.001), and similar results were found in VI. Moreover, survival analysis showed that pT stage (P<0.001), pN stage (P=0.001), pTNM stage (p<0.001), VI (P=0.001) and LI (P<0.001) were associated with DFS in ESCC. Furthermore, multivariate analysis suggested that pT stage (RR=1.4, P =0.032), pN stage (RR=1.9, P<0.001) and LI (RR=1.5, P=0.008) were independent predictive factors for DFS. Finally, relapse was observed in 110 patients (lymph node metastasis, 78 and distant, 32) and 147 patients with cancer-related deaths. Subanalysis showed that LI-positive patients had higher lymph node metastasis, although there was no significant difference (32.1% vs. 15.6%, P=0.100). Conclusions LI and VI were common in ESCC; they were all survival predictors for patients with ESCC, and LI was independent. Patients with positive LI were more likely to suffer lymph node metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In the current study, the results were in accordance with their findings, and both LI and VI were predictors of survival. Moreover, most of the previous studies combined LI and VI together and investigated the effects of prognosis on lymphatic and vascular invasion together [22][23][24].…”

Section: Discussionmentioning

confidence: 99%

The role of vascular invasion and lymphatic invasion in predicting recurrent thoracic oesophageal squamous cell carcinoma

Yao

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…De Marco et al reported that age did not have any significant influence on curative resections and long-term survival in patients with gastric cancer (23). In contrast to these conclusions, Park et al and Yu et al showed that older age was a prognostic factor for worse 5-year survival even for patients after gastric cancer resection with stage I according the TNM classification (22,25). Hsu et al performed a retrospective review of the cohort of patients with gastric cancer who underwent curative resection and found that older age was associated with a higher overall perioperative complications rate (p=0.035) and perioperative mortality rate (p=0.015).…”

Section: Discussionmentioning

confidence: 98%

Clinicopathological Prognostic Factors Determining Outcomes of Treatment in Gastric Cancer Surgery

Kulig

Pach

Majewska

et al. 2022

In Vivo

View full text Add to dashboard Cite

Background/Aim: The purpose of this study was to examine the impact of clinicopathological prognostic factors on tumor resectability, perioperative complications, and 5year survival rates in patients with gastric cancer treated surgically. Patients and Methods: A cohort of 834 patients operated on for gastric cancer between 2007 and 2016 was analyzed. Results: Patients over 70 years of age manifested a significantly higher rate of overall complications, systemic complications, surgical complications, perioperative mortality, and a worse 5-year survival. The diffuse type according to the Lauren classification was an independent prognostic factor for perioperative mortality. TNM stage significantly influenced resectability and 5-year survival rates. Furthermore, the presence of distant metastases (M1 stage) significantly increased the rates of overall complications, systemic complications, and perioperative mortality. Conclusion: Although TNM stage was the most important prognostic factor for resectability, perioperative complications and 5-year survival, other clinicopathological prognostic factors, such as age, and Lauren type also significantly affected treatment outcomes in gastric cancer surgery.

show abstract

“…However, evidence of the survival benefits of adjuvant chemotherapy for early gastric cancer is lacking. Although there is no lymph node metastasis in T2N0M0 gastric cancer, some patients still experience recurrence[ 10 - 16 ]. Therefore, it is important to identify patients with stage T2N0M0 gastric cancer who are at high risk of recurrence and may require adjuvant chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…According to the 8th edition of the American Joint Committee on Cancer (AJCC) guidelines for gastric cancer, T2 was defined as tumor invasion of the muscularis propria[ 9 ]. It is controversial whether adjuvant chemotherapy is necessary for stage T2N0M0 gastric cancer[ 10 - 16 ]. Previous studies have suggested that patients with stage I gastric cancer cannot benefit from adjuvant chemotherapy[ 17 ].…”

Section: Introductionmentioning

confidence: 99%

A new scoring system to evaluate adjuvant chemotherapy for patients with T2N0M0 gastric cancer after D2 gastrectomy

Xu¹,

Kang²,

Xiong³

et al. 2022

World J Gastroenterol

View full text Add to dashboard Cite

BACKGROUND At present, there is insufficient medical evidence to determine whether adjuvant chemotherapy is necessary for T2N0M0 gastric cancer. AIM To obtain a risk score to assess the need for adjuvant chemotherapy in patients with T2N0M0 gastric cancer. METHODS We identified 325 patients with pathological T2N0M0 stage primary gastric cancer at the National Cancer Center between 2011 and 2018. Univariate and multivariate Cox regression analyses were performed to predict factors affecting prognosis. Vascular invasion, tumor site, and body mass index were assessed, and a scoring system was established. We compared the survival outcomes and benefits of adjuvant chemotherapy between the different subgroups. RESULTS Five-year survival rates of the score 0, 1, 2, and 3 groups were 92%, 95%, 80%, and 50%, respectively ( P < 0.001). In the score 2-3 group, five-year survival rates for patients in the adjuvant chemotherapy group and postoperative observation group were 95% and 61%, respectively ( P = 0.021). CONCLUSION For patients with T2N0M0 stage gastric cancer and two or more risk factors, adjuvant chemotherapy after D2 gastrectomy may have a survival benefit.

show abstract

Prognostic Factors in Stage IB Gastric Cancer after Surgical Resection

Cited by 9 publications

References 28 publications

The role of vascular invasion and lymphatic invasion in predicting recurrent thoracic oesophageal squamous cell carcinoma

The role of vascular invasion and lymphatic invasion in predicting recurrent thoracic oesophageal squamous cell carcinoma

Clinicopathological Prognostic Factors Determining Outcomes of Treatment in Gastric Cancer Surgery

A new scoring system to evaluate adjuvant chemotherapy for patients with T2N0M0 gastric cancer after D2 gastrectomy

Contact Info

Product

Resources

About